Ischaemic Heart Disease, CYP2C19polymorphisms, clopidogrel resistance
Conditions
Interventions
Study setting: Outpatient clinic of the Institute of Cardiology, National Hospital of Sri Lanka.
Intervention: Administration of an increased (150mg/daily) dose of clopidogrel for 14 days followed b
Sponsors
Medical Research Institute
Eligibility
Inclusion criteria
Inclusion criteria: 1. Resistance to platelet aggregation on clopidogrel 75 mg/Day. inhibition is defined as: 5 µM ADP: < 50% ADP-induced decrease in the maximum platelet aggregation from the baseline level. 20 µM ADP: < 70% ADP-induced decrease in the maximum platelet aggregation from the baseline level. 2. Presence or absence of Gene CYP2C19 polymorphism detected using qualitative PCR 3. Ischemic heart Disease.
Exclusion criteria
Exclusion criteria: 1. Bleeding disorders 2. Platelet dysfunctions due to Renal/Kidney diseases or Liver diseases 3. The patients who are taking drugs like; cyclooxygenase-1 inhibitors (Ibuprofen, Naproxen, Indomethacin, Ketorolac, ect);Thienopyridines (Prasugreul); Gp IIb/IIIa receptor inhibitors (Abciximab, Tirofiban, Epifibatide);Antiplatelet agents (Ticagrelor, ect) Beta-lactam antibiotics; Cilostazol; Dipyridamole or nutritional supplements like SSRIs, Dextran and Alcohol. 3. Blood transfusion/donation – within last 3 months. 4. Patients given 600mg loading dose. – within last 2 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Clopidogrel resistance measured by Platelet function testing using Light transmission platelet aggregometry and defined as: 5 µM ADP: < 50% ADP-induced decrease in the maximum platelet aggregation from the baseline level. 20 µM ADP: < 70% ADP-induced decrease in the maximum platelet aggregation from the baseline level [14 days after starting the intervention] | — |
Secondary
| Measure | Time frame |
|---|---|
| None [None] | — |
Countries
Sri Lanka
Contacts
Public ContactDr Nishali Ekanayaka
Consultant Pathologist
Outcome results
None listed